News & Updates
Filter by Specialty:
How safe for the heart is hydroxychloroquine use in RA patients?
The risks of sudden cardiac arrest or ventricular arrythmia (SCA/VA) and major adverse cardiovascular event (MACE) are comparable between methotrexate (MTX) and hydroxychloroquine (HCQ) in older patients with rheumatoid arthritis (RA), reports a study.
How safe for the heart is hydroxychloroquine use in RA patients?
01 Jul 2022
Do bDMARDs prevent osteoporotic fractures in RA patients?
Use of biological disease-modifying antirheumatic drugs (bDMARDs) appears to have no benefit in the prevention of osteoporotic fractures among patients with rheumatoid arthritis (RA), according to the results of a recent study.
Do bDMARDs prevent osteoporotic fractures in RA patients?
01 Jul 2022
Ultra-high-dose methylcobalamin may reduce clinical progression in early-stage ALS
Ultra-high-dose methylcobalamin (MeCbl) slowed functional decline in individuals with early-stage amyotrophic lateral sclerosis (ALS) with moderate progression, the JETALS* study has shown.
Ultra-high-dose methylcobalamin may reduce clinical progression in early-stage ALS
01 Jul 2022
Novel PPARγ modulator shows therapeutic potential in acne vulgaris
In the treatment of patients with acne vulgaris, the investigational peroxisome proliferator-activated receptor-γ (PPARγ) modulator N-acetyl-GED-0507-34-LEVO (NAC-GED) 5% gel appears to help clear lesions and improve acne severity while being safe, according to the results of a phase IIb study.
Novel PPARγ modulator shows therapeutic potential in acne vulgaris
01 Jul 2022
Ibrutinib-bendamustine-rituximab combo promising for older patients with mantle-cell lymphoma
A treatment combination comprising the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus bendamustine and rituximab, followed by rituximab maintenance therapy, improved progression-free survival (PFS) in older patients with untreated mantle-cell lymphoma, according to results of the SHINE* trial presented at ASCO 2022.